In-Transit Melanoma and a Flaring Joint: Choosing a Local Therapy Over a Systemic One
A single patient whose melanoma is entirely reachable by a needle and whose joints have their own, independent stake in whatever gets injected into his immune system next. The disagreement is genuinely open: nobody here is confident how his rheumatoid arthritis would actually respond.
F.J., a 71-year-old man, has lived with rheumatoid arthritis for over twenty years, controlled well enough on methotrexate that he still manages his own small orchard most mornings, picking apples from a stepladder he refuses to give up despite his family's objections. A BRAF-wild-type melanoma resected from his lower leg eight years ago has recurred as multiple in-transit cutaneous and subcutaneous nodules along the same limb -- six lesions in total, none larger than 2cm, with staging imaging confirming no nodal or visceral spread.
His disease pattern is close to the textbook description of who benefits most from talimogene laherparepvec, an oncolytic herpesvirus injected directly into accessible lesions: OPTiM, the pivotal trial, found its durable response rate concentrated specifically in earlier-stage, cutaneous-and-nodal-only disease like his, with a 16.3 percent durable response rate against 2.1 percent for the comparator, and a toxicity profile dominated by local injection-site reactions and flu-like symptoms rather than the systemic immune activation that defines checkpoint inhibitor therapy. That distinction is the entire reason it's under real consideration here: his rheumatoid arthritis, stable for years, is a disease whose flare risk with systemic checkpoint blockade is documented but genuinely hard to predict for any one patient -- retrospective cohorts of patients with pre-existing autoimmune disease who received anti-PD-1 therapy report flare rates in a wide range, with most flares manageable but a real minority severe enough to require additional immunosuppression of their own.
Nothing about his RA has changed recently, and nothing about his melanoma currently reaches beyond a field a needle can access -- which is exactly what makes this a genuine choice between two real options rather than an obvious step toward the more powerful one. His most recent DAS28 disease-activity score, checked at his rheumatologist's routine visit two months ago, sits comfortably in remission range -- a baseline worth documenting precisely now, before any decision, so a future flare has something concrete to be measured against.
A local therapy for a patient whose joints have their own stake
His disease is almost a textbook match for OPTiM's own best-responding subgroup -- cutaneous and in-transit only, no nodal or visceral spread, treatment-naive. Durable response rate was 16.3 percent against 2.1 percent for the comparator in that population, and the toxicity is predominantly local injection-site reaction and flu-like symptoms rather than the systemic immune activation his rheumatoid arthritis makes genuinely risky. I'd start T-VEC.
I'd point out that T-VEC's own combination trial with pembrolizumab, MASTERKEY-265, failed to show added benefit over pembrolizumab alone -- which tells us something about T-VEC's real ceiling as a standalone systemic strategy, even acknowledging his disease is currently confined to an injectable field. His RA is a real factor, but retrospective cohorts of anti-PD-1 use in pre-existing autoimmune disease report most flares as manageable, not treatment-ending.
I take the local-toxicity argument seriously for him specifically. I just don't think 'most flares are manageable' should be read as 'his flare would be manageable' when we genuinely don't have data specific enough to promise that.
I don't think either of you is wrong about the data -- I think the data genuinely doesn't resolve this for one specific patient's joints. 'Most flares are manageable' is a real finding and also cold comfort if his turns out to be the one that isn't, especially given how much of his daily function depends on hands and joints that have been stable for years.
Given that his disease truly is confined to what a needle can reach right now, I'd start with T-VEC alone -- not because it's proven superior, but because it lets us learn how his disease behaves without spending the systemic option before we have to. If new lesions appear beyond an injectable field, or if T-VEC's local response proves insufficient, pembrolizumab moves back onto the table with a real, informed conversation about his RA rather than a decision made before we needed to make it.
Agreed: start T-VEC injections to all six lesions, with systemic pembrolizumab held in explicit reserve rather than ruled out, contingent on either disease extension beyond an injectable field or an inadequate local response.
Not agreed, and named directly rather than papered over: the Second Medical Oncologist remains doubtful T-VEC alone will achieve durable control given its modest single-agent ceiling, and would have preferred starting low-dose pembrolizumab now with close rheumatology monitoring rather than waiting; the Rheumatologist's preference to learn how his disease behaves on the lower-risk option first carried the plan for now, with an explicit follow-up date set to reassess rather than an open-ended wait.